Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Therapy for cystic fibrosis--the end of the beginning?

Davis PB.

N Engl J Med. 2011 Nov 3;365(18):1734-5. doi: 10.1056/NEJMe1110323. No abstract available.

PMID:
22047565
2.

Potentiators for cystic fibrosis - targeting the underlying molecular defect.

Patel S, Sinha IP, Dwan K, Echevarria C, Schechter M, Southern KW.

Paediatr Respir Rev. 2015 Jun;16(3):162-4. doi: 10.1016/j.prrv.2015.04.003. Epub 2015 Apr 20. Review. No abstract available.

PMID:
26002404
3.

Cystic fibrosis transmembrane conductance regulator dysfunction and its treatment.

Hull J.

J R Soc Med. 2012 Jun;105 Suppl 2:S2-8. doi: 10.1258/jrsm.2012.12s001. Review. No abstract available.

4.

Carrier screening for cystic fibrosis in the new era of medications that restore CFTR function.

Massie J, Castellani C, Grody WW.

Lancet. 2014 Mar 8;383(9920):923-5. doi: 10.1016/S0140-6736(13)61092-2. Epub 2013 Aug 30. Review. No abstract available.

PMID:
23992917
5.

Update in Cystic Fibrosis 2014.

Ong T, Ramsey BW.

Am J Respir Crit Care Med. 2015 Sep 15;192(6):669-75. doi: 10.1164/rccm.201504-0656UP. Review. No abstract available.

PMID:
26371812
6.

Ivacaftor for patients with cystic fibrosis.

Wainwright CE.

Expert Rev Respir Med. 2014 Oct;8(5):533-8. doi: 10.1586/17476348.2014.951333. Epub 2014 Aug 22. Review.

PMID:
25148205
7.

Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.

Pettit RS.

Ann Pharmacother. 2012 Jul-Aug;46(7-8):1065-75. doi: 10.1345/aph.1R076. Epub 2012 Jun 26. Review.

PMID:
22739718
8.

Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.

Patel S, Sinha IP, Dwan K, Echevarria C, Schechter M, Southern KW.

Cochrane Database Syst Rev. 2015 Mar 26;(3):CD009841. doi: 10.1002/14651858.CD009841.pub2. Review.

PMID:
25811419
9.

Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.

Kotha K, Clancy JP.

Ther Adv Respir Dis. 2013 Oct;7(5):288-96. doi: 10.1177/1753465813502115. Epub 2013 Sep 3. Review.

PMID:
24004658
10.

Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis.

Derichs N.

Eur Respir Rev. 2013 Mar 1;22(127):58-65. doi: 10.1183/09059180.00008412. Review.

11.

Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation.

Sermet-Gaudelus I.

Eur Respir Rev. 2013 Mar 1;22(127):66-71. doi: 10.1183/09059180.00008512. Review.

12.

Cystic fibrosis--what are the prospects for a cure?

Kumar S, Tana A, Shankar A.

Eur J Intern Med. 2014 Nov;25(9):803-7. Review.

PMID:
25447947
13.

Cystic fibrosis in an era of genomically guided therapy.

Barrett PM, Alagely A, Topol EJ.

Hum Mol Genet. 2012 Oct 15;21(R1):R66-71. Epub 2012 Aug 21. Review. Erratum in: Hum Mol Genet. 2013 May 1;22(9):1911.

PMID:
22914736
14.

CFTR protein repair therapy in cystic fibrosis.

Quintana-Gallego E, Delgado-Pecellín I, Calero Acuña C.

Arch Bronconeumol. 2014 Apr;50(4):146-50. doi: 10.1016/j.arbres.2013.07.013. Epub 2013 Oct 2. Review. English, Spanish.

15.

Cystic fibrosis in the era of genomic medicine.

Milla CE.

Curr Opin Pediatr. 2013 Jun;25(3):323-8. doi: 10.1097/MOP.0b013e328360dbf5. Review.

PMID:
23652683
16.

Modifying disease in cystic fibrosis: current and future therapies on the horizon.

Ong T, Ramsey BW.

Curr Opin Pulm Med. 2013 Nov;19(6):645-51. doi: 10.1097/MCP.0b013e328365ab5f. Review.

PMID:
24048086
17.

Cystic fibrosis transmembrane regulator correctors and potentiators.

Rowe SM, Verkman AS.

Cold Spring Harb Perspect Med. 2013 Jul 1;3(7). pii: a009761. doi: 10.1101/cshperspect.a009761. Review.

18.

Cystic fibrosis: a review of pathophysiology and current treatment recommendations.

Peters S.

S D Med. 2014 Apr;67(4):148-51, 153. Review. No abstract available.

PMID:
24791377

Supplemental Content

Support Center